- Report
- May 2026
- 391 Pages
Global
From €5196EUR$5,850USD£4,527GBP
- Report
- September 2025
- 144 Pages
Global
From €3552EUR$3,999USD£3,095GBP
- Report
- January 2026
- 120 Pages
Global
From €4219EUR$4,750USD£3,676GBP
- Report
- March 2026
- 200 Pages
Global
From €4437EUR$4,995USD£3,866GBP
- Report
- July 2025
- 215 Pages
Global
From €4437EUR$4,995USD£3,866GBP
- Report
- October 2025
- 160 Pages
Global
From €2982EUR$3,358USD£2,598GBP
€3509EUR$3,950USD£3,057GBP
- Report
- October 2025
- 160 Pages
Global
From €2982EUR$3,358USD£2,598GBP
€3509EUR$3,950USD£3,057GBP
- Report
- August 2025
- 150 Pages
Global
From €2982EUR$3,358USD£2,598GBP
€3509EUR$3,950USD£3,057GBP
- Report
- April 2026
- 126 Pages
Global
From €3500EUR$4,221USD£3,156GBP
- Report
- October 2025
- 83 Pages
Global
From €4308EUR$4,850USD£3,753GBP
- Report
- July 2025
- 100 Pages
United States
From €5285EUR$5,950USD£4,605GBP
- Report
- January 2023
- 388 Pages
Global
From €4693EUR$5,468USD£3,950GBP
- Report
- March 2024
- 80 Pages
Europe
From €5285EUR$5,950USD£4,605GBP
- Report
- September 2023
- 236 Pages
Global
From €5285EUR$5,950USD£4,605GBP
- Report
- December 2024
- 200 Pages
Global
From €2221EUR$2,500USD£1,935GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1777EUR$2,000USD£1,548GBP
- Drug Pipelines
- April 2025
- 70 Pages
Global
From €1332EUR$1,500USD£1,161GBP
- Report
- July 2024
- 100 Pages
Global
From €3331EUR$3,750USD£2,902GBP
- Report
- April 2025
- 85 Pages
Saudi Arabia
From €3109EUR$3,500USD£2,709GBP
- Report
- January 2025
- 82 Pages
India
From €3109EUR$3,500USD£2,709GBP

The Carbapenem market is a subset of the Antibiotics market, which is composed of drugs used to treat bacterial infections. Carbapenems are a class of antibiotics that are used to treat serious infections caused by bacteria that are resistant to other antibiotics. They are typically used as a last resort when other antibiotics have failed. Carbapenems are generally well-tolerated and have a low risk of side effects.
Carbapenems are used to treat a wide range of infections, including pneumonia, urinary tract infections, and skin and soft tissue infections. They are also used to treat infections caused by multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA).
The Carbapenem market is highly competitive, with several major players. These include Merck & Co., Pfizer, GlaxoSmithKline, AstraZeneca, and Sanofi. Other companies in the market include Allergan, Novartis, and Daiichi Sankyo. Show Less Read more